Search - tctmd.com

Displaying 401 - 420 of 492

Sort: Relevancy | Date

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

News Daily News

ARB Use Linked to Suicide in New Study, but Is the Finding Real?

Michael O'Riordan

October 18, 2019

News Daily News

DAPT Cuts Saphenous Vein Graft Failure After CABG: Meta-analysis

Michael O'Riordan

October 17, 2019

News Daily News

Dramatic Swings in Household Income Linked to CVD Risk: ARIC

Michael O'Riordan

October 09, 2019

News Conference News HFSA 2019

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

L.A. McKeown

September 24, 2019

News Conference News HFSA 2019

Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF

L.A. McKeown

September 23, 2019

News Conference News HFSA 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

L.A. McKeown

September 18, 2019

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

L.A. McKeown

September 16, 2019

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

News Conference News ESC 2019

CONDI-2/ERIC-PPCI Puts the Kibosh on Ischemic Conditioning in STEMI

Yael L. Maxwell

September 01, 2019

News Conference News ESC 2019

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

Shelley Wood

August 31, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for August 2019

Shelley Wood

August 30, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

Best Strategy Questioned for NSTE ACS Patients With Prior CABG

Shelley Wood

August 05, 2019

News Daily News

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

Shelley Wood

July 23, 2019

News Daily News

Sudden, ‘Biologically Implausible’ Rise in Valsartan-Linked Neoplasms After 2018 Recall

Marcus A. Banks

July 12, 2019

News Conference News SCAI 2019

Cancer and CV Disease Care: What’s Known? What Lies Ahead for Cardio-Oncology?

Yael L. Maxwell

May 30, 2019

News Conference News ESC Heart Failure 2019

Steep Rise in PCI for Ischemic Heart Failure Seen in Sweden, but Survival Favors CABG

Shelley Wood

May 28, 2019

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

Advertisement

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

ARB Use Linked to Suicide in New Study, but Is the Finding Real?

DAPT Cuts Saphenous Vein Graft Failure After CABG: Meta-analysis

Dramatic Swings in Household Income Linked to CVD Risk: ARIC

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

CONDI-2/ERIC-PPCI Puts the Kibosh on Ischemic Conditioning in STEMI

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

TCTMD’s Top 10 Most Popular Stories for August 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Best Strategy Questioned for NSTE ACS Patients With Prior CABG

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

Sudden, ‘Biologically Implausible’ Rise in Valsartan-Linked Neoplasms After 2018 Recall

Cancer and CV Disease Care: What’s Known? What Lies Ahead for Cardio-Oncology?

Steep Rise in PCI for Ischemic Heart Failure Seen in Sweden, but Survival Favors CABG

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content